To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Local Injection of Ketorolac vs Triamcinolone Acetonide for De Quervain's Tenosynovitis

Download
Share
Reprints
Cite This
About
+ Favorites
Download
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
November 2022

Local Injection of Ketorolac vs Triamcinolone Acetonide for De Quervain's Tenosynovitis

Vol: 299| Issue: 1| Number:1| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Comparison of the effect of ketorolac versus triamcinolone acetonide injections for the treatment of de Quervain's tenosynovitis: a double-blind randomized controlled trial

BMC Musculoskelet Disord. 2022 Sep 1;23(1):831.

Contributing Authors:
S Suwannaphisit P Suwanno W Fongsri C Chuaychoosakoon

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Sixty-four patients with de Quervain's tenosynovitis were randomized to receive a local injection of ketorolac (n=31) or triamcinolone acetonide (n=33). Outcomes of interest included pain scores on a Visual Numeric Rating Scale (VNRS), the Disabilities of the Arm, Shoulder and Hand (DASH) score, grip strength and pinch strength, and the need for additional injection, assessed at 6 weeks follow up....

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue